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ABSTRACT
We used mouse hepatic chromatin enriched with an
FXR antibody and chromatin immunoprecipitation-
sequencing (ChIP-seq) to evaluate FXR binding on
a genome-wide scale. This identified 1656 FXR-
binding sites and 10% were located within 2kb of a
transcription start site which is much higher than
predicted by random occurrence. A motif search
uncovered a canonical nuclear receptor IR-1 site,
consistent with in vitro DNA-binding studies
reported previously. A separate nuclear receptor
half-site for monomeric receptors such as LRH-1
was co-enriched and FXR activation of four newly
identified promoters was significantly augmented
by an LRH-1 expression vector in a co-transfection
assay. There were 1038 genes located within 20kb of
a peak and a gene set enrichment analysis showed
that genes identified by our ChIP-seq analysis are
highly correlated with genes activated by an FXR-
VP16 adenovirus in primary mouse hepatocytes
providing functional relevance to the genome-wide
binding study. Gene Ontology analysis showed
FXR-binding sites close to many genes in lipid, fatty
acid and steroid metabolism. Other broad gene
clusters related to metabolism, transport, signaling
andglycolysis werealsosignificantly enriched. Thus,
FXR may have a much wider role in cellular
metabolism than previously appreciated.
INTRODUCTION
The farnesoid X nuclear receptor (FXR; NR1H4) is
mainly expressed in the liver and distal small intestine
and is a key regulator of enterohepatic bile acid
metabolism (1). Bile acids are secreted by the liver and
released into the small intestine during a meal where
they aid the absorption of dietary fat and fat-soluble
vitamins (2). Bile acids have been proposed as endogenous
FXR agonists and are natural detergents that become
toxic at high levels, which can occur when the normally
tight regulation of their synthesis, transport and excretion
is perturbed (3). Studies with mice fed synthetic FXR
agonists have suggested that FXR plays a key role not
only in cholesterol and bile acid metabolism but also in
the regulation of glucose metabolism (3–5).
FXR interacts with retinoid X receptor (RXR; NR2B)
as a requisite heterodimeric partner and binds to DNA
elements called FXR response elements (FXREs) (6). All
nuclear receptors have a highly conserved zinc ﬁnger
DNA-binding domain that binds to a similar response
element and individual nuclear receptors bind to either a
single half-site if they bind as a monomer or to a dimeric
response element composed of two half-sites with a
variable orientation and spacing relative to one another
(7). An in vitro DNA sites selection assay showed that
FXR prefers binding to an inverted repeat of the ideal
sequence 50-AGGTCA-30 where the monomers are
separated by 1nt (IR-1) (8). This speciﬁcity is also
supported by the functional analysis of a limited number
of FXR activated promoters (9).
To extend the limited information available from the
relatively small set of individually characterized FXR
target genes and to identify putative new targets and
provide more insight into the mechanism for how FXR
activates gene expression, we have evaluated FXR binding
on a genome-wide scale in hepatic chromatin using a
combination of chromatin immunoprecipitation (ChIP)
coupled with high-throughput DNA sequencing (ChIP-
seq) (10) We identiﬁed 1656 binding sites for FXR in the
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motif search suggested that all contain an identiﬁable IR-1
site. Most of the sites are located primarily in intergenic
and intronic regions but there is a signiﬁcant enrichment
of FXR-binding sites within 2kb of transcription start
sites (TSS) for known genes. Interestingly, an additional
nuclear receptor half-site was signiﬁcantly co-enriched
along with the IR-1 element suggesting that FXR activates
gene expression in combination with a co-binding
monomeric nuclear receptor. Transient reporter studies
analyzing four genes where the IR-1 and associated
additional half-site are located in promoter regions
shows that FXR activation was signiﬁcantly augmented
by including an expression construct for LRH-1 (11), a
liver enriched monomeric nuclear receptor that is known
to preferentially bind nuclear receptor half sites and has
already been shown to augment promoter activation by
LXR (12–14).
MATERIALS AND METHODS
Additional data
Additional information related to this study can be found
at http://cbcl-1.ics.uci.edu/public_data/FXR/.
Chromatin immunoprecipitation followed by
sequencing (ChIP-seq)
Twelve-week-old C57BL6 male mice were purchased from
Jackson Laboratory and were fed a standard chow diet
and allowed to adapt to a 12h dark/12h light cycle for
2weeks (15). All animals were sacriﬁced at the end of the
dark cycle and ChIP assays from liver were performed as
previously described (15) with a minor modiﬁcation.
Chromatin was harvested and subjected to an
immunoselection process, which required the use of
antibodies against FXR (sc-13063; Santa Cruz
Biotechnology, Santa Cruz, CA) or mouse IgG (Sigma)
as a control. To prepare samples for the ChIP-seq, after
isolating the ChIP-enriched DNA, gene-speciﬁc
enrichment for known FXR target promoters from SHP
in the FXR chromatin relative to IgG control chromatin
was veriﬁed. The qPCR primers for the mouse SHP
promoters were as follows: Forward, 50GAGAGCCT
GAGACCTTGGTG30; Reverse 50CGTGGCCTTGCTATCACTTT30.
Approximately 20ng of ChIP enriched DNA or control
DNA was sent to Ambry Genetics (Aliso Viejo, CA) for
high throughput DNA sequencing. The samples were
blunt ended and adapters were ligated to the ends,
according to the library preparation protocol from
Illumina. Then DNA fragments with 200±25bp in
length were selected for the construction of ChIP-seq
DNA library. After size selection, all the resulting
ChIPed DNA fragments were ampliﬁed and sequenced
simultaneously using Solexa/Illumina Genome Analyzer
(by Ambry Genetics).
Quantitative PCR, microarray analysis
Manual ChIP conﬁrmation on the randomly selected
putative FXR target genes from lipid metabolism
category or negative control regions was by quantitative
PCR (qPCR) (16). Final ChIPed and control DNA
samples were analyzed in triplicate with L32 as internal
control. For this assay, we used pre-designed and
validated qPCR primer speciﬁc to the genomic region
being interrogated.
Cell culture, transient transfection and reporter
gene assays
Transfection assays were slightly modiﬁed from a previous
report (14). 293T cells were maintained in high glucose
Dulbecco’s Modiﬁed Eagle Medium (DMEM) (Gibco),
4.5g/ml glucose, 0.1mM non-essential amino acids,
100units/ml penicillin, 100mg/ml streptomycin and 10%
fetal bovine serum (FBS). 293T cells (2 10
5 cells/well)
were seeded in 24-well plates and transfected with
luciferase reporter and expression (FXR and RXR)
plasmids using Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA) according to manufacturer’s protocol. A
pCMV–b-gal expression construct was included in every
transfection as a normalization control. After 6h cells
were treated with either DMSO or GW4064. After 24h
of treatment, cells were harvested and assayed for
luciferase and b-gal activities.
Adenovirus preparation and infection
Adenovirus containing either the transactivation domain
of herpes simplex virus, VP16, or mouse FXRa2 fused to
VP16 were generated as previously described (17).Primary
mouse hepatocytes were isolated from wild-type C57BL/6
mice and maintained in DMEM (25mM glucose/10%
fetal bovine serum) as described (18).Hepatocytes were
cultured for three days before infection with adenovirus
expressing VP16 or FXRa2-VP16 at a m.o.i. of 10.
Infected cells were then incubated with vehicle (0.01%
DMSO) or 2mM GW4064 in DMSO for 48h. RNA was
isolated using Trizol reagent (Invitrogen, CA) and
microarrays were performed as described (19).
Plasmid constructs for promoter activation assay
The promoter regions of Adfp (–826 to +287) and Pcx
(–1246 to+110) were cloned by PCR ampliﬁcation using
mouse genomic DNA as template, followed by
recombination with pDONR221
TM vector (Invitrogen,
Carlsbad, CA) according to Gateway Cloning technology
(Invitrogen, Carlsbad, CA). The entry clone constructs
were then transferred into the luciferase reporter vector
pLUC-GW kindly provided by J. Imbert (Institute
Paoli-Calmettes, Marseille, France). All constructs were
veriﬁed by DNA sequencing. Oligo primers for the Adfp
and Pcx promoter region used in PCR ampliﬁcation are as
follows:
Adfp 50, TCCCTGAACCCTTATGACTCC; Adfp 30, CAGAAG
GACGTGCAAACAGA; Pcx 50, CACCCTAGGTGCTCTGCTTC; Pcx
30, GAGCCATACCTGCTCTGGA, Adfp 50 with ATT sites, GGG
GACAAGTTTGTACAAAAAAGCAGGCTTCCCTGAACCCTTATGACTCC;
Adfp with ATT site 30, GGGGACCACTTTGTACAAGAAAGCTG
GGTCAGAAGGACGTGCAAACAGA; Pcx with ATT site 50,
GGGGACAAGTTTGTACAAAAAAGCAGGCTCACCCTAGGTGCTCTGCT
6008 Nucleic Acids Research, 2010,Vol.38, No. 18TC; Pcx with ATT site 30, GGGGACCACTTTGTACAAGAAAGCTG
GGTAGAGCCATACCTGCTCTGGA.
Plasmid constructs containing FXR-binding sites for
LRH-1 co-activation assay
The DNA fragments containing FXR-binding sites from
SHP, Pcx, Rdh9 and Pemt and which also contain an
additional half site near them were cloned by PCR
ampliﬁcation using mouse genomic DNA as template,
and using primers containing sites for restriction
enzymes KpnI and NheI on either side. The DNA
fragments and pGL3 Luciferase Reporter Vector
(Promega) were then digested with KpnI and NheI,
which generated compatible ends for cloning. All
constructs were veriﬁed by DNA sequencing. The
luciferase activity was observed during the reporter assay
after transfection of 293T cells. Primers for PCR
ampliﬁcations: SHP 50, ACTTTGAGGTCCGACACACC; SHP 30,
AGTGGCTGTGAGATGCAGGT; Pemt 50, AGAAAGTCCAGGTGGC
TTGA; Pemt 30, GCCAGTGTCAGATGGTCCTT; Rdh9 50,
GCAGGAGCCGTATGTAAAGC; Rdh9 30, GAAGCCAAGCAGAGAG
AGAGA; Pcx 50, CACCCTAGGTGCTCTGCTTC; Pcx 30, GAGC
CATACCTGCTCTGGA. Restriction enzyme sites were then
added to these primer oligos by PCR ampliﬁcation:
KpnI, ATGGACGGTACC; NheI, ATGGACGCTAGC.
ChIP-Seq data analysis
Preprocessing sequence data. The ChIP-seq dataset was
analyzed to identify peaks which contain binding sites of
FXR binding. Short reads of 39bp were produced from
Solexa/Illumina Genome Analyzer, and mapped to a
reference genome by Ambry Genetics using ELAND,
allowing one mismatch. Short sequence reads that
mapped to simple and complex repeats or that were not
unique by chance were removed from the analysis. We
converted these ﬁles to BED ﬁles using the ChIP-Seq
mini 2.0.1 suite (10). The BED ﬁles were used as input
to downstream processing, as well as visualization in the
UCSC Genome Browser (http://genome.ucsc.edu/index.
html). The wiggle (WIG) ﬁles for display of our data as
custom annotation tracks in UCSC Genome Browser can
be downloaded from http://cbcl-1.ics.uci.
edu/public_data/FXR/.
Finding peaks. To determine where the FXR bound to the
genome, we looked for areas where there were signiﬁcantly
more enriched reads mapped in the ChIP sample than in
the IgG. This was accomplished using MACS (20) with
the parameters of mfold 10, bandwidth 300bp, P-value
1 10
 5 and false discovery rate (FDR) 5%.
Distance to IR-1 sites from the summit of each
peak. MACS provides a summit for every peak, which
can be regarded as the center of the peak.It is where
there is the maximum number of overlapping reads, and
is the most likely location of the true binding site.For each
peak with an IR-1 site, we determined the distance from
the best IR-1 site to this summit.If they overlapped, we
score the distance as zero. To give a sense of the
enrichment, we placed an arbitrarily located site of
the same length in each peak, determined the distance to
the summit, and plotted the results on the same histogram.
Distance from peak to transcription start sites (TSSs)
For each peak, the distance from the peak to the nearest
transcription start site was determined, and plotted.
The TSSs were taken from a RefSeq ﬁle obtained from
NCBI.The background was determined by placing peaks
at random locations on the genome and by determining
distances to TSS.
Motif analysis
DNA sequences were retrieved using Galaxy (http://main
.g2.bx.psu.edu) and used for motif search using MEME
(21). MEME represents motifs as position-dependent
letter-probability matrices (PWM). The PWM was used
to ﬁnd a score for any 13-bp sequence; each letter in the
sequence has a likelihood given in the PWM, these are
summed to ﬁnd a score for the sequence, with a higher
score meaning it is more likely to be the motif in question.
We used the PWM to ﬁnd scores for every position along
an entire chromosome (excepting coding and repeat
regions), and found the average score and standard
deviation. Then when a new sequence was tested, we
obtained its score from the PWM, subtracted the
average, and divided by the standard deviation. This
provided us a z-score for any sequence, which was
converted into a P-value via a standard normal curve.
Annotation of genes and gene ontology (GO) analysis
All FXR-binding sites were assigned to nearest genes
based on the Mus musculus NCBI m37 genome
assembly (mm9; July 2007). GO analysis of FXR target
genes was conducted by using the NIH Database for
Annotation, Visualization, and Integrated Discovery
(DAVID; http://david.abcc.ncifcrf.gov/) (22). This
analysis was used to classify the nearest gene list into
functionally related gene groups by using ‘PANTHER
Biological Process’ term.
Kolmogorov–Smirnov analysis
The obtained ChIP-seq data was compared with
expression microarray data by using a Kolmogorov–
Smirnov (KS) plot, a modiﬁed method of gene set
enrichment analysis (GSEA) (23). The KS plot tests the
null hypothesis that the ranks of the genes identiﬁed by
ChIP-seq is uniformly distributed throughout the FXR
expression microarray. A KS plot was obtained by
calculating the running sum statistics for our ChIP-seq
gene set to observe enrichment in the ranked gene list
from expression microarray data.
Co-regulator analysis
To ﬁnd the binding sites for the co-regulators near the
FXR-binding sites, we masked all the FXR IR-1sites
(P<0.001) in the peak sequences with ‘N’, and scanned
the masked region ±150bp for co-regulator binding sites
Nucleic Acids Research, 2010,Vol.38, No. 18 6009using MEME. We also applied an enumeration-based
method, k-mer analysis, to the sequences to search for
the co-regulator motifs. For the k-mer analysis, we did
each motif length separately, from 6 to 15bp. We
counted every occurance of each k-mer in the peak
regions, as well as in a background sequence (1.5MB of
promoter sequence), and calculated z-scores as the
statistical signiﬁcance for its enrichment in the peak
sequences compared to a background dataset. The
PWM for the motif was used to compare against
JASPAR database using STAMP (24).
RESULTS
Identiﬁcation of novel FXR-binding sites
Hepatic chromatin from 12 C57BL/6 mice was pooled and
processed for ChIP with an antibody to FXR or a control
IgG as described in ‘Materials and methods’ section and
previously (25). The quality of the chromatin and
speciﬁcity of the antibody were conﬁrmed by comparative
ChIP analysis using a known FXR-binding site in the SHP
promoter (12,13) with chromatin from WT or FXR-
knockout (FXR-KO) mice (Supplementary Figure S1).
ChIP using the WT chromatin resulted in a signiﬁcant
enrichment for FXR binding to the SHP promoter
whereas the signal was signiﬁcantly attenuated using
FXR-KO chromatin.
Next, we subjected the ChIPed DNA from WT
chromatin to ChIP-seq analysis using the Solexa/
Illumina Genome Analyzer. This ChIP-seq method
generated a relevant FXR transcription factor binding
dataset that contained 4–5 million individual 39-nt
sequence reads produced in each run (Figure 1A). The
high numbers contribute to high sensitivity and signal-
to-noise ratios, and to relative comprehensiveness for the
mouse genome (10). To ﬁnd peaks bound by FXR, we
used Model-based Analysis of ChIP-seq (MACS), which
was designed to analyze data generated by short read
sequencers such as from the Solexa/Illumina Genome
Analyzer (20) to ﬁrst estimate peak size and location
(Supplementary Figure S2). Then, using P-value and
FDR cutoﬀs of  1 10
 5 and  5% respectively, we
identiﬁed 1656 genomic sites occupied by FXR
(Figure 1A, http://cbcl-1.ics.uci.edu/public_data/FXR).
The distribution of FXR-binding regions were
predominantly in intergenic regions (44%), and introns
(32%) (Figure 1B) with 10% also located within 2-kb 50
of a transcription start site (TSS) for a known gene. In
contrast, when the genomic location for randomly
generated peaks of similar size was estimated, only 2%
were localized to within 2kb of a TSS. Thus, the 10%
ﬁgure for sites within 2kb of a TSS indicates there
is non-random association of FXR-binding sites
(P<0.005) in close proximity to TSS regions (Figure 1B).
The sequence reads were aligned as a track onto the
mouse genome using the University of California at
Santa Cruz (UCSC) genome browser (http://genome
.ucsc.edu/index.html), and visual inspection of several
sites conﬁrmed that the peaks identiﬁed by MACS
correspond to sites of over-represented sequence tabs.
Several examples are shown in Figure 2.
Motif analysis for FXR binding
FXR-binding speciﬁcity has been analyzed in vitro using a
binding site enrichment procedure where one-half site was
ﬁxed as a nuclear receptor consensus site and random
DNA was analyzed in the second half site. Additionally,
there have been functional studies of a relatively small set
of well characterized FXR target genes. Together, these
analyses suggest that the preferred FXR site is an ‘IR-10
element which is composed of two half sites of the
canonical nuclear receptor half site consensus sequence
50-AGGTCA-30 oriented in an inverted repeat orientation
and separated by a single nucleotide (8,9).
To determine how well these prior studies are predictive
for FXR binding on a genome-wide scale, we used the
motif ﬁnding program MEME (21) to search for
enriched motifs in the peaks from our ChIP-seq data set.
The highest scoring motif in the analysis was an IR-1
(E-value=6.5e
 828) and all 1656 FXR peaks contained
the IR-1 site based on the MEME analysis. The position
weight matrix (PWM) for the IR-1 from the MEME
analysis was used to scan all our FXR peaks again using
a more stringent cutoﬀ (P<0.001). Using this stringent
criterion, an IR-1 was present in 76% (1259/1656,
P<0.001) of the 1656 peaks (Figure 3A). This indicates
that our genome-wide analysis of in vivo binding sites is
consistent with the IR-1 as the preferred cis-acting element
for binding of FXR. It is interesting that the sequence of
one-half site is much more strongly enriched than the
other. This is similar to the genome-wide binding
analyses for PPAR–g/RXR as well (26,27).
A
B
Figure 1. ChIP-seq analysis for FXR binding to DNA in hepatic
chromatin. (A) Summary of ChIP-seq analysis by MACS. Given
mfold 10 and sonication size (bw) 300bp, MACS searched 2bw
window area across the genome to ﬁnd genomic peaks with tags
more than mfold enriched relative to a random tag genome distribution.
The results were obtained using the parameters of P-value cutoﬀ
1 10
 5 and FDR 5%. (B) Mapping of FXR-binding regions on
genome-wide scale relative to RefSeq mouse genes. The ‘promoter’
and ‘downstream’ are deﬁned as 2kb of 50 or 30 ﬂanking regions.
Intergenic region refers to all locations other than ‘promoter’, ‘50
UTR’, ‘exon’, ‘intron’, ‘30UTR’ or ‘downstream’.
6010 Nucleic Acids Research, 2010,Vol.38, No. 18In the MACS analysis of the short sequence reads,
a summit for every peak is identiﬁed based on combining
reads matching to each strand and the summit is
deﬁned as the midpoint for the overlapping reads.
Theoretically, this is the most likely location of the
actual site of FXR–DNA interaction. We calculated
the distance from the best IR-1 site in each IR-1
containing peak to the corresponding peak summit. By
this analysis, the IR-1 sites were signiﬁcantly closer to
the peak-summits relative to randomly placed motifs,
conﬁrming the high accuracy of the ChIP-seq peak
mapping technique and providing more conﬁdence that
the IR-1 is actually the site of recognition for FXR
(Supplementary Figure S3). Most peaks contain one IR-
1 element but a signiﬁcant fraction contains more than
one (Supplementary Figure S4). Interestingly, there are
over 1.7 million predicted IR-1 sites in the mouse
genome with P<0.001 using the PWM calculated from
our data set (Figure 3B), however there are only 1656
(0.09%) that are occupied by FXR in liver chromatin
using our stringent cutoﬀ.
Genes located close to FXR binding in liver
To begin to examine the functional signiﬁcance of FXR
binding on a whole genome scale, the nearest gene was
determined for each FXR peak. Then, we examined
the distance from the center of each peak to the
transcription start site (TSS) of the nearest gene. The
FXR-binding peaks were enriched around the TSS
compared to a set of randomly generated motifs of
similar length (Figure 4).
There were 1038 genes located within 20kb of a peak
and we analyzed this list using the DAVID Gene Ontology
(GO) resource (http://david.abcc.ncifcrf.gov/) and
grouped them into enriched broad categories using
PANTHER (22). This analysis showed there was a
strong enrichment for genes in metabolic processes, and
the most signiﬁcantly enriched genes were associated with
metabolism of lipids including fatty acids and cholesterol
(Table 1).
Validation of FXR-binding peaks
We randomly picked nineteen gene-associated peaks for
manual site conﬁrmation with speciﬁc primers and
quantitative PCR (qPCR). This analysis demonstrated
that 17 exhibited at least 1.5-fold enrichment relative to
the IgG samples corresponding to an 89% rate of
validation (Figure 5A). We also picked PCR validated
primers for 11 other genomic target sites that were
negative for peak assignment and none of these showed
any enrichment in the FXR antibody enriched chromatin
(Supplementary Figure S5).
AB
D C
E
Figure 2. Representative view of a ChIP-seq peak. The novel FXR binding sites, mapped onto University of California at Santa Cruz (UCSC)
genome browser, were identiﬁed in several genes presented here. Shown are chromosomal locations according to the July 2007 Mouse Genome
Assembly (mm9). Gene associated peaks are noted by the arrows. (A) Pemt (phosphatidylethanolamine N-methyltransferase). (B) Fasn (fatty acid
synthase). (C) Aifm2 (apoptosis-inducing factor 2, mitochondrian). (D) Scarb1 (scavenger receptor B-1). (E) Adfp (adipose diﬀerentiation related
protein).
Nucleic Acids Research, 2010,Vol.38, No. 18 6011Correlation between FXR binding and FXR-dependent
gene regulation
Next, we analyzed the 1038 genes that were located within
20kb of an FXR peak by a gene set enrichment analysis
(GSEA) using the modiﬁed KS test (23). In this analysis,
the FXR site proximal genes were analyzed for their
distribution in a mRNA microarray expression set where
the genes were rank-ordered for diﬀerential expression in
primary hepaocytes infected with a control adenovirus or
a recombinant virus that expresses a constutively active
FXR-VP16 fusion protein. The analysis showed a highly
signiﬁcant running enrichment score because the genes
identiﬁed by ChIP-seq were preferentially located toward
the top of the diﬀerentially expressed gene list (Figure 5B,
P=1.68e
 16). Thus, it is highly likely that the ChIP-seq
identiﬁed sites correspond to functional sites of FXR
action.
To more directly validate the functionality of our
FXR-binding sites from ChIP-seq, we analyzed Adfp
(adipose diﬀerentiation-related protein,  826 to+287)
and Pcx (pyruvate carboxylase,  1246 to +110), two
genes from our data set that were previously unknown
to be FXR responsive, and that contained putative
FXR-binding sites in their proximal promoters, by
making luciferase reporter constructs that were then
analyzed for FXR activation by transient transfection
(Figure 5C). When co-transfected with FXRa and
RXRa expression vectors, activity of both Pcx and
Adfp promoters was stimulated by a combination of
FXR/RXR plus the synthetic FXR agonist GW4064
(Figure 5C). This conﬁrms that the promoters for two
newly identiﬁed putative FXR target genes are directly
stimulated by FXR.
Co-regulatory DNA-binding partners of FXR
To determine if there were additional transcription factor-
binding sites that might be preferrentially co-enriched with
the FXR peaks, we masked the IR-1 element and re-
searched the sequence around each FXR peak summit.
This revealed that an additional nuclear receptor half-
site was present in 896 peaks (71% of 1259, P<0.001)
of the FXR-binding peaks containing IR-1 sites
(Figure 6A). Because the sequence of the half site is
contained within all of the IR-1 sites we were concerned
that the co-enriched half sites might represent ‘weak’ IR-1
elements that failed to reach the P<0.001 cut oﬀ value.
However, when we analyzed this by a sequence
replacement method we estimated that at least 80%
represent true half-sites (Supplementary Figure S6).
Interestingly, the IR-1 FXR peak and the additional
half-site are located relatively close together with most
having the two elements within 50 bases of each other
(Figure 6B).
Monomeric nuclear receptors bind to receptor half-sites
and the liver receptor homologue (LRH-1) is an abundant
hepatic protein of this class. Additionally, LRH-1
functionally interacts with LXR to activate Cyp7A1 and
Fasn promoters in the mouse (12–14).
To analyze whether FXR and LRH-1 might also
function together, we used three complementary
approaches. First, we performed manual ChIP studies
for LRH-1 binding to several of the gene promoters
predicted to share FXR and LRH-1 sites (Figure 6C).
This analysis revealed that LRH-1 also binds close to all
of these FXR peak regions. Next, we chose four genes that
A 1656/1656, E = 6.5e-828
1259 (76%), p = 0.001 
B
Figure 3. Motif analysis. (A) Consensus FXR-binding motif Weblogo
found within the peaks identiﬁed by ChIP-seq using MEME program.
The IR-1 motif was found in 76% of the FXR-binding sites when
PWM from MEME analysis was used. (B) Genome-wide location of
IR-1 sites around mouse genome. Its PWM was obtained by using
MEME.
Figure 4. Distance from the center of each peak identiﬁed as FXR-
binding site to the transcription start site (TSS) of the nearest gene.
The TSSs were taken from NCBI RefSeq database.Each black line
represents a separate set of random sequences of similar length.
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Figure 5. Peak validation. (A) Manual ChIP conﬁrmation for ChIPed liver DNA by qPCR. Nineteen FXR-binding peaks were randomly selected
for validation by gene-speciﬁc ChIP qPCR. Fold Change is the fold increase for the signal from DNA enriched by FXR antibody relative to a
control IgG. Fasn was used as a positive control. Data were normalized to the housekeeping gene L32. (B) KS plot. The gene list for the ChIP-seq
peaks that were located within 20kb of a known gene was compared for their correlation to a set of genes that were activated by infection of primary
mouse hepatocytes with a recombinant adenovirus expressing the constitutive FXRa2-VP16 hybrid protein as described in the text. Genes in the
expression microarray were ranked by fold diﬀerence (x-axis) and the graph plots the running enrichment score. (C) Promoter activation assay.
Luciferase reporter plasmids with promoters from genes from our ChIP-seq dataset were constructed. Pcx (pyruvate carboxylase) and Adfp (adipose
diﬀerentiation-related protein) were previously unknown to be FXR target genes, and contained putative FXR-binding sites in their proximal
promoters and tested for FXR activation by transient transfection. Expression of the reporters was stimulated by GW4064 treatment in cells co-
transfected with FXR and RXR expression vectors. Fasn (fatty acid synthase) was used as a positive control.
Table 1. Summary of DAVID GO analysis of nearest genes to FXR-binding regions
Top GO Categories of nearest genes to peaks
PANTHER BIOLOGICAL PROCESS Count P–value FDR
BP00019: Lipid, fatty acid and steroid metabolism 58 5.48E-08 6.97265E-05
BP00036: DNA repair 86 2.46E-07 3.12E-04
BP00143: Cation transport 164 1.45E-06 1.84E-03
BP00033: Pyrimidine metabolism 26 3.54E-05 4.50E-02
BP00141: Transport 71 5.77E-05 7.33E-02
BP00008: Tricarboxylic acid pathway 17 1.35E-04 0.172142101
BP00104: G-protein mediated signaling 144 1.40E-04 0.17745439
BP00286: Cell structure 137 1.44E-04 0.182437201
BP00071: Proteolysis 198 2.22E-04 0.282634364
BP00276: General vesicle transport 49 3.36E-04 0.426752545
BP00063: Protein modiﬁcation 115 3.66E-04 0.465131227
BP00153: Complement-mediated immunity 25 8.04E-04 1.017828781
BP00076: Electron transport 41 2.99E-03 3.743358089
BP00014: Amino acid biosynthesis 25 3.07E-03 3.837211045
BP00013: Amino acid metabolism 18 3.10E-03 3.877861993
BP00044: mRNA transcription regulation 336 3.66E-03 4.561346276
BP00142: Ion transport 87 7.08E-03 8.643459039
BP00005: Glycolysis 18 7.58E-03 9.221152371
BP00103: Cell surface receptor mediated signal transduction 86 8.51E-03 10.29998477
BP00193: Developmental processes 78 1.11E-02 13.186538
BP00298: Glycogen metabolism 18 1.92E-02 21.87988309
A total of 1038 genes for peaks located within 20kb of a gene were used to group into enriched functionally important categories using PANTHER.
Nucleic Acids Research, 2010,Vol.38, No. 18 6013contained both an FXR-binding peak and also an
additional half-site within their proximal promoters.
These included Pcx, Rdh9, Pemt and SHP. We prepared
luciferase reporter plasmids for each and analyzed their
responsiveness to the combination of FXR and LRH-1
in reporter assays. The analysis in Figure 7 shows that
each promoter was activated by FXR and the inclusion
of the LRH-1 expression vector signiﬁcantly enhanced the
FXR responsiveness on all four promoters in a dose-
dependent manner. Lastly, we used a co-immunopre-
citipation analysis to evaluate whether the two proteins
might directly interact with each other. Liver chromatin
was incubated with a control IgG or an antibody to LRH-
1 followed by an immunoblotting analysis with an
antibody to FXR. The results in Figure 8 show that
LRH-1 was speciﬁcally precipitated in a complex by the
FXR antibody.
DISCUSSION
In this study, we present the genome-wide proﬁling of
FXR-binding sites in mouse liver chromatin. This ChIP-
seq analysis revealed 1656 FXR genomic-binding sites
with a high degree of conﬁdence (P<1 10
 5,
FDR<5%). Most of the identiﬁed FXR-binding sites
are located in distal intergenic regions (44%) or introns
(32%), with fewer sites localizing to more proximal
promoter regions (10%; Figure 1B). The high distribution
of binding sites within intergenic and intron regions are
consistent with similar reports for other nuclear receptor
transcription factors, including PPARg (26,27), estrogen
receptor a (28), and the androgen receptor (29).
However, it should be emphasized that although only
10% of the binding sites were localized to within 2kb 50
of a TSS, this is signiﬁcantly higher than expected based
on random localization (Figure 1B). Thus, even though
the FXR-binding sites show a broad genome-wide
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Figure 7. Co-transfection assay for FXR-LRH-1 activation. 293T cells were transfected with luciferase reporter plasmids indicated with or without
expression vectors pCMX-FXR2 (100ng/well), pCMX-RXR (100ng/well), and LRH-1. After 6 hr of transfection, cells were treated with DMSO or
synthetic FXR agonist GW4064 as indicated and cells were harvested after 24h. Luciferase and -gal assays were then performed on cell extracts. The
data are representative of at least three experiments. In the experiment shown, SHP, Pcx, and Rdh9 were analyzed in triplicate and * indicates
p<0.05. In this experiment, Pemt was analyzed in duplicate only. (A) SHP (small heterodimer partner). (B) Pcx (pyruvate carboxylase). (C) Rdh9
(retinol dehydrogenase 9). (D) Pemt (phosphatidylethanolamine N-methyltransferase).
Figure 6. Co-regulator analysis. (A) Co-regulatory DNA-binding motif
identiﬁed along with FXR-binding motif. The IR-1 elements in each
FXR peak were masked and then FXR-binding peaks were searched
for motifs located within 150bp on either side of each peak. (B)
Distance from the best IR-1 site to midpoint of closest additional
NR half site. (C) qPCR analysis of 12 peaks for LRH-1 binding.
Results are presented as fold change from control as in
Supplementary Figure 1.
6014 Nucleic Acids Research, 2010,Vol.38, No. 18distribution, the 10% indicates signiﬁcant preference for
promoter proximity as well. Additionally, even though
most sites were located intragenically or within introns,
they do localize close to known TSS (Figure 4).
While there is evidence for agonist dependent changes in
binding of some hormone receptors to DNA such as
estrogen receptor (ER) in cultured cell models (30), the
inﬂuences of agonist binding on DNA occupancy for
nuclear receptors in vivo in general and for those where
endogenous metabolically derived compounds function as
agonists in particular is complicated and not clearly
understood. In the course of our studies, we ﬁrst
compared the genome-wide association of FXR in livers
of a control group fed normal chow versus a group fed
chow supplemented with GW4064, currently the synthetic
agonist of choice for FXR. While there was a mild
induction of gene expression for a handful of known
FXR target genes in this analysis, there was no statistically
signiﬁcant diﬀerence in genome-wide binding of FXR
revealed by this comparison (data not shown). Because
the GW4064 agonist is not very potent at stimulating
endogenous target genes in vivo, it is not clear if the lack
of diﬀerence in DNA binding is meaningful. This is an
important area of study that we will investigate in the
future when more potent in vivo FXR agonists become
available.
Our analysis showed that 76% of the peaks contain a
stringently identiﬁed IR-1 element (P<0.001; Figure 3A).
This discovery both conﬁrms and extends the data from
in vitro DNA-binding site selection and the small number
of individual gene analyses that have been reported (9).
Additionally, the Weblogo obtained from the position
weight matrix emphasizes that the bases in one of the
half-sites are highly preferred whereas there is relaxed
ﬂexibility and less preference observed for the second
half site. A similar half-site asymmetry preference was
also revealed in the Weblogo for PPARg/RXR (26,27)
where a conserved DR-1 site showed a higher preference
for bases in the 30 half site, which is known to be
speciﬁcally occupied by the RXR monomer. An
explanation for this was likely revealed by the crystal
structure for the PPARg/RXR dimer bound to a DR-1
site (31). The structure revealed that the zinc ﬁnger
region in the RXR DNA-binding domain makes more
half site-speciﬁc base contacts compared to the zinc-
ﬁnger region of PPARg.
Because the FXR recognition site is a palindrome, the
rotational symmetry makes it impossible to assign a
speciﬁc monomer to each half-site without any more
information. However, based on the information above,
it is likely that the more highly conserved half site of the
IR-1 is bound by RXR.
It is interesting that there are over 1.7 million sites in the
mouse genome that match our IR-1 PWM with P<0.001.
The fact that only 1656 (0.09%) were occupied by FXR in
our analysis indicates that other local genomic features
such as hepatic nucleosome positioning and epigenetic
markers that alter chromatin architecture and genomic
access inﬂuence FXR site occupancy. Additionally, co-
occupancy by neighboring DNA-binding factors like
LRH-1 likely play a signiﬁcant role in addition to the
primary sequence of the IR-1 motif in deﬁning where
FXR is localized in hepatic chromatin.
We compared the list of genes within 20kb of a FXR
peak to a list of genes that were rank-ordered by
signiﬁcance for diﬀerential mRNA expression in primary
hepatocytes infected with an adenovirus that expresses a
constitutively active FXRa–VP16 hybrid protein relative
to a control adenovirus. This gene set enrichment analysis
(GSEA) was displayed by a KS plot (23) which tests for
how well the two data sets correlate with each other. This
analysis showed a high degree of correlation between FXR
binding and FXR-dependent gene activation (Figure 5B;
P=1.68e
 16). Thus, the FXR-binding peaks likely
represent functional FXR response elements. It should
be noted that the FXR–VP16 fusion protein would
activate through genomic sites where wild-type FXR
might repress gene expression and there have been
reports that FXR binding may repress gene expression
(32). Thus, our GSEA provides a good correlation
between FXR binding by ChIP-seq and target gene
identiﬁcation but it does not allow us to diﬀerentiate
between genes that are normally activated or repressed
directly through FXR response elements.
After ﬁrst masking the IR-1 sites we repeated the
de novo motif search around the peak summits
(±150bp) to search for putative enriched FXR co-
regulatory DNA-binding partners. This analysis revealed
that an additional nuclear half site, 50-AGGTCA-30, was
present close to 71% of the IR-1 containing FXR peaks
(Figure 6). It is unlikely that FXR interacts directly with
this additional half site because this would have been
revealed as a peak summit when the sequence reads were
mapped to the genome. We also analyzed directly whether
the half-sites might correspond to ‘weak’ IR-1 sites that
fell below our statistical threshold. This analysis revealed
that at least 80% of the identiﬁed half-sites are true half
sites (Supplementary Figure S5). It should be noted that
FXR has been shown to possibly interact with DNA as a
monomer (33) and we cannot rule out with certainty that
some of the half-sites might bind a monomeric form
of FXR.
Figure 8. FXR and LRH-1 proteins interact with each other. Hepatic
chromatin was subjected to immunoprecipitation with a LRH-1
antibody (lanes 3 and 4) or control IgG (lanes 5 and 6) and the
precipitated material was analyzed by immunoblotting with an
antibody to FXR. Duplicate samples were analyzed and the positions
for FXR in the starting material is also shown. Input is shown in lanes
1 and 2. The asterisk marks the migration of the IgG heavy chain.
Nucleic Acids Research, 2010,Vol.38, No. 18 6015Because monomeric nuclear receptors bind to isolated
half-sites and LRH-1 is a liver enriched monomeric
nuclear receptor, we proposed that LRH-1 would be a
good candidate for an FXR co-regulatory protein.
Because most FXR-binding sites were localized to
introns or intergenic regions it would be diﬃcult to
construct reporter genes that retain the native spacing
for the proximal promoter together with the intronic/
intergenic FXR/RXR response element. Therefore, to
analyze LRH-1 as a putative FXR co-regulatory partner
we performed gene speciﬁc ChIP analysis of 12 peaks
predicted to contain LRH-1-binding sites (Figure 6C)
and we chose four genes where the FXR/RXR and
associated extra half-sites were located within the
proximal promoter region for promoter activation
assays. In this analysis, all four promoter–reporters
conﬁrmed that FXR/RXR activation was signiﬁcantly
enhanced by the addition of an LRH-1 expression vector
in the transfection assay (Figure 7). We also showed that
FXR and LRH-1 associate with each other directly by co-
immunoprecipitation (Figure 8). These three approaches
strongly support our hypothesis that FXR and LRH-1
function together to activate hepatic gene expression.
It is interesting to note that there are additional
monomeric nuclear receptors that are expressed in the
liver such as the reverbs and RORs which are regulated
by heme and sterol agonists respectively (34,35) and SF-1
which is very similar to LRH-1 (36). Reverbs and RORs
are expressed in reciprocal diurnal patterns in the liver. It
will be interesting to analyze these additional monomeric
nuclear receptors in future studies for their potential roles
as FXR co-regulatory factors that might be associated
with a diurnally regulated pattern of FXR activity.
In a GO analysis, the broad category of lipid and fatty
acid metabolism was the most signiﬁcant gene cluster
linked to the FXR peak associated genes as expected.
However, genes of glycolysis also showed a signiﬁcant
enrichment as well. This is interesting because FXR has
been shown to be involved in modulating glucose
metabolism associatead with diabetes in mice (3–5). In
addition, a number of other broad-based gene clusters
related to metabolism, transport and signaling were also
signiﬁcantly enriched. These latter results suggest that
FXR may have a much wider role in regulating cellular
metabolism than has been proposed to date. Indeed,
identiﬁcation of new FXR targets within these categories
may explain the pleiotropic eﬀects on metabolism and
cellular physiology noted in both animal studies and
patients with bile acid disorders (1,37).
While we were completing the analyses for our study, a
comparative evaluation of the genome-wide pattern of
FXR binding to hepatic and intestinal chromatin was
reported (38). Overall, the binding results are very
comparable but the two approaches have some diﬀerences
in that the synthetic FXR agonist GW4064 was added a
few hours before sacriﬁce by Thomas et al and the
sequence mapping and analysis were performed by
diﬀerent methods. Interestingly, Thomas et al also
identiﬁed an IR-1 element with a co-enriched additional
nuclear receptor half site close to the FXR peaks. As
mentioned above, we did not observe a consistent
diﬀerence in FXR binding by the addition of the
GW4064 agonist. Thus, we were not surprised that
overall the results are similar to ours. In addition to
deﬁning the genomic sites for FXR binding, our study
goes further and also provides functional evidence that
FXR is likely to aﬀect expression of the genes associated
with the peaks. We also provide evidence that LRH-1 is an
important monomeric nuclear receptor partner for FXR
that binds to the co-enriched nuclear receptor half site to
co-activate gene expression.
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